Idarucizumab

Mechanism of action

Reversal agent of dabigatran.

Humanised monoclonal antibody fragment that binds to dabigatran, reversing its anticoagulation effect.

Indications and dose

Side-effects

Thrombosis

Pharmacokinetics

Routes: Intravenous

Onset: Minutes

Duration: 24 hours

Metabolism: biodegradation into peptides and amino acids

Half-life of elimination: 0.75-10 hours

Excretion: Urine

Directions for administration

Give undiluted.

Medicinal forms

Solution for infusion

1 vial = 2.5 g in 50 ml (50 mg in 1 ml)

‍

References

https://bnf.nice.org.uk/drugs/idarucizumab/ 

https://www.uptodate.com/contents/idarucizumab-drug-information?search=idarucizumab&source=panel_search_result&selectedTitle=1~21&usage_type=panel&kp_tab=drug_general&display_rank=1